Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A DNA-PKcs mutation in a radiosensitive T–B– SCID patient inhibits Artemis activation and nonhomologous end-joining
Mirjam van der Burg, Hanna IJspeert, Nicole S. Verkaik, Tuba Turul, Wouter W. Wiegant, Keiko Morotomi-Yano, Pierre-Olivier Mari, Ilhan Tezcan, David J. Chen, Malgorzata Z. Zdzienicka, Jacques J.M. van Dongen, Dik C. van Gent
Mirjam van der Burg, Hanna IJspeert, Nicole S. Verkaik, Tuba Turul, Wouter W. Wiegant, Keiko Morotomi-Yano, Pierre-Olivier Mari, Ilhan Tezcan, David J. Chen, Malgorzata Z. Zdzienicka, Jacques J.M. van Dongen, Dik C. van Gent
View: Text | PDF
Research Article Immunology

A DNA-PKcs mutation in a radiosensitive T–B– SCID patient inhibits Artemis activation and nonhomologous end-joining

  • Text
  • PDF
Abstract

Radiosensitive T–B– severe combined immunodeficiency (RS-SCID) is caused by defects in the nonhomologous end-joining (NHEJ) DNA repair pathway, which results in failure of functional V(D)J recombination. Here we have identified the first human RS-SCID patient to our knowledge with a DNA-PKcs missense mutation (L3062R). The causative mutation did not affect the kinase activity or DNA end-binding capacity of DNA-PKcs itself; rather, the presence of long P-nucleotide stretches in the immunoglobulin coding joints indicated that it caused insufficient Artemis activation, something that is dependent on Artemis interaction with autophosphorylated DNA-PKcs. Moreover, overall end-joining activity was hampered, suggesting that Artemis-independent DNA-PKcs functions were also inhibited. This study demonstrates that the presence of DNA-PKcs kinase activity is not sufficient to rule out a defect in this gene during diagnosis and treatment of RS-SCID patients. Further, the data suggest that residual DNA-PKcs activity is indispensable in humans.

Authors

Mirjam van der Burg, Hanna IJspeert, Nicole S. Verkaik, Tuba Turul, Wouter W. Wiegant, Keiko Morotomi-Yano, Pierre-Olivier Mari, Ilhan Tezcan, David J. Chen, Malgorzata Z. Zdzienicka, Jacques J.M. van Dongen, Dik C. van Gent

×

Figure 2

ID177 harbors a DSB repair defect.

Options: View larger image (or click on image) Download as PowerPoint
ID177 harbors a DSB repair defect.
(A) Clonogenic survival assay using w...
(A) Clonogenic survival assay using wild-type (FN1) fibroblasts, patient fibroblasts (ID177), and fibroblasts from an Artemis-deficient patient (Artemis-1; ref. 25) and an LIG4-deficient patient (SC2; ref. 29). Fibroblasts were irradiated with increasing x-ray doses. ID177 fibroblasts were RS. Error bars represent the SD from 3 independent experiments. (B) Numbers of γ-H2AX foci per nucleus were determined at indicated time points after irradiation (average number of foci per nucleus in 40 cells) in wild-type (VH10), ID177, and Artemis-deficient fibroblasts (Artemis-6; ref. 31). Error bars represent the SD from 2–4 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts